Tenofovir, COX inhibitors and zileuton during cancer immunotherapies: Up-regulated TNF-alpha increases antigen driven lymphocyte proliferation

Molecular Immunology

Volumn 40, Issue 5, 2003, Pages 297-303

  Kast, R E ^a  

^a UNIVERSITY OF VERMONT   (United States)

Author keywords

Adenylate cyclase; Adjuvant; Cancer immunology; Cyclooxygenase; Non steroidal anti inflammatory drugs; Tenofovir; Tumor necrosis factor alpha; Zileuton

Indexed keywords

ACYCLIC NUCLEOSIDE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ANTIGEN; ARACHIDONATE 5 LIPOXYGENASE; ARACHIDONATE 5 LIPOXYGENASE INHIBITOR; BLOCKING AGENT; CARRIER PROTEIN; CYCLIC AMP; DICLOFENAC; INDOMETACIN; KETOROLAC; LEUKOTRIENE; PROSTAGLANDIN E; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; TENOFOVIR; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VECTOR; ZILEUTON;

ACTIVE IMMUNIZATION; ADENOCARCINOMA; ALLOSTERISM; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CELL MATURATION; CYTOKINE PRODUCTION; CYTOKINE RELEASE; DENDRITIC CELL; DIGESTIVE SYSTEM CANCER; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMORAL IMMUNITY; LYMPHOCYTE PROLIFERATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; REVIEW; T LYMPHOCYTE;

EID: 0041926408     PISSN: 01615890     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0161-5890(03)00144-5     Document Type: Article

References (62)

1. Abbas N., Zou L.P., Pelidou S.H., Winblad B., Zhu J. Protective effect of Rolipram in EAN: protection is associated with down-regulation of IFN-gamma and inflammatory cytokines as well as up-regulation of Il-4 in peripheral nervous system. Autoimmunity. 32:2000;93-99.
2. Ahlers J.D., Belyakov I.M., Matsui S., Berzofsky J.A. Mechanisms of cytokine synergy essential for vaccine protection against viral challenge. Int. Immunol. 13:2001a;897-908.
3. Ahlers J.D., Belyakov I.M., Matsui S., Berzofsky J.A. Signals delivered through TCR instruct Il-12 receptor expression: Il-12 and TNF-alpha synergize for Il-12R expression at low antigen dose. Int. Immunol. 13:2001b;1433-1442.
4. Arpinati M., Green C.L., Heimfeld S., Heuser J.E., Anasetti C. G-CSF mobilizes Th 2 inducing dendritic cells. Blood. 95:2000;2484-2490.
5. Barth R.J. Jr., Camp B.J., Martuscello T.A., Dain B.J., Memoli V.A. The cytokine microenvironment of human colon carcinoma: lymphocyte expression of TNF and Il-4 predicts improved survival. Cancer. 78:1996;1168-1178.
6. Bauman S.K., Huffnagle G.B., Murphy J.W. Effects of TNF-alpha on dendritic cell accumulation in lymph nodes draining immunization site and the impact on the anti-cryptococcal cell mediated immune response. Infect. Immun. 71:2003;68-74.
7. Benlalam H., Labarriere N., Linard B.et al. Comprehensive analysis of the frequency of recognition of melanoma associated antigen by CD8 melanoma infiltrating lymphocytes: implications for immunotherapy. Eur. J. Immunol. 31:2001;2007-2015.
8. Berzofsky J.A., Ahlers J.D., Belyakov I.M. Strategies for designing and optimizing new generation vaccines. Nat. Rev. Immunol. 1:2001;209-219.
9. Brunner C., Seiderer J., Schlamp A.et al. Enhanced dendritic cell maturation by TNF-alpha or cytadine-phosphate-guanosine DNA drives activation in vitro and therapeutic anti-tumor immune responses in vivo. J. Immunol. 165:2000;6278-6286.
10. Candido K.A., Shimizu K., McLaughlin J.C.et al. Local administration of dendritic cells inhibits established breast tumor growth: implications for apoptosis inducing agents. Cancer Res. 61:2001;228-236.
11. Chen N., Reiss C.S. Distinct roles of eicosanoids in the immune response to viral encephalitis. Viral Immunol. 15:2002;133-146.
12. Duan R.S., Wang H.B., Yang J.S., Scallon B., Link H., Xiao B.G. Anti-TNF antibodies suppresses the development of experimental allergic myasthenia gravis. J. Autoimmun. 19:2002;169-174.
13. Flammand N., Surete M.E., Picard S., Bourgoin S., Borgeat P. cAMP mediated inhibition of 5-LO translocation and leukotriene biosynthesis in human neutrophils. Mol. Pharm. 62:2002;250-256.
14. Ghezzi P., Sacco S., Agnello D.et al. LPS induces Il-6 in brain and serum largely through TNF production. Cytokine. 12:2000;1205-1210.
15. Green E.A., Choi Y., Flavell R.A. Pancreatic lymph node derived CD4+/CD25+ T reg cells: highly potent regulators of diabetes that require TRANCE-RANK signals. Immunity. 16:2002;183-191.
16. Hajek R., Butch A.W. Dendritic cell biology and the application of dendritic cells to immunotherapy of multiple myeloma. Med. Oncol. 17:2000;2-15.
17. Hallstrand T.S., Henderson W.R. Leukotriene modifiers. Med. Clin. North Am. 86:2002;1009-1033.
18. Henning R., Ding X.Z., Tong W.G.et al. 5-LO and LTB4 receptor are expressed in human pancreatic cancers but not in pancreatic ducts in normal tissue. Am. J. Pathol. 161:2002;421-428.
19. Ho L.J., Chang D.M., Shiau H.Y.et al. Aspirin differentially regulates endotoxin induced Il-12 and TNF production in human dendritic cells. Scand. J. Rheumatol. 30:2001;346-352.
20. Hudson J.M., Castilleja A., Murray J.L.et al. Growth and antigen recognition of TIL from human breast cancer. J. Interferon Cytokine Res. 18:1998;529-536.
21. Itoh T., Ueda Y., Kawashima I.et al. Immunotherapy of solid cancer using dendritic cells pulsed with the HLA-A-24 restricted peptide of CEA. Cancer Immunol. Immunother. 51:2002;99-106.
22. Jawien J. A new insight into aspirin induced asthma. Euro. J. Clin. Invest. 32:2002;134-138.
23. Kane, S., Altschuler, E.L., Kast, R.E., 2003. Bupropion continues to benefit Crohn's disease course: an update. Gastroenterology, in press.
24. Kast R.E. Crohn's disease remission with phenelzine. Gastroenterology. 115:1998;1034-1035.
25. Kast R.E. Non-steroidal anti-inflammatory drugs might also be pro-inflammatory by increasing TNF. Biomed. Pharmacother. 54:2000a;168-169.
26. Kast R.E. TNF has positive and negative feedback cycles centered on cAMP. Int. J. Immunopharm. 22:2000b;3-8.
27. Kast R.E. Feedback between glial TNF and gp120 from HIV infected cells helps maintain infection and destroy neurons. Neuroimmunomod. 10:2002;85-92.
28. Kast R.E., Altschuler E.L. Remission of Crohn's disease on bupropion. Gastroenterology. 121:2001;1260-1261.
29. Kast, R.E., Altschuler, E.L., 2003a. TNF in hepatitis B: potential role of bupropion. J. Hepatol.39, 131-133.
30. Kast, R.E., Altschuler, E.L., 2003b. Bupropion lowers TNF in congestive heart failure. Internat. J. Cardiol., submitted for publication.
31. Khan A.Q., Shen Y., Wu Z.Q., Wynn T.A., Snapper C.M. Endogenous pro- and anti-inflammatory cytokines differentially regulate an in vivo humoral response to Streptomyces pneumoniae. Infect. Immun. 70:2002;749-761.
32. Kim E.Y., The H.S. TNF type 2 receptor (p75) lowers the threshold of T cell activation. J. Immunol. 167:2001;6812-6820.
33. Kojima M., Morisaki T., Uchiyama A.et al. Association of enhanced COX-2 expression with possible local immunosuppression in human colorectal carcinomas. Ann. Surg. Oncol. 8:2001;458-465.
34. Lei H., Ju D.W., Yu Y.et al. Induction of potent antitumor response by vaccination with tumor lysate pulsed macrophages engineered to secrete M-CSF and IFN-gamma. Gene Ther. 7:2000;707-713.
35. Lu Y., Yamauchi N., Koshita Y.et al. Administration of sub-tumor regression doses of TNF to mice with pre-existing tumors augments the vaccination effect of TNF gene modified tumor through induction of MHC class 1 molecule. Gene Ther. 8:2001;499-507.
36. McHugh R.S., Whitters M.J., Piccirillo C.A.et al. CD4+/CD25+ immunoregulatory T cells: gene expression analysis reveals a functional role for the glucocorticoid induced TNF receptor. Immunity. 16:2002;311-323.
37. Musselli C., Ragupathi G., Gilewski T., Panageas K.S., Spinat Y., Livingston P.O. Reevaluation of the cellular immune response in breast cancer patients. Int. J. Cancer. 97:2002;660-667.
38. Ohd J.F., Nielsen C.K., Campbell J. Expression of LTD4 receptor CystLT 1, COX-2 and other cell survival factors in colorectal adenocarcinomas. Gastroenterology. 124:2003;57-70.
39. Osnes L.T., Haug K.B., Joo G.B.et al. Aspirin potentiates LPS induced fibrin formation and TNF synthesis in whole blood. Thromb. Haemost. 83:2000;868-873.
40. O'Sullivan B.J., Thomas R. CD40 ligation conditions DC antigen presenting function through sustained activation of NFkB. J. Immunol. 168:2002;5491-5498.
41. Rangel J.R.M., Estrada G.I., De La Luz G.H.M., Aguilar L.D., Marquez R., Hemandez P.R. The role of prostaglandin E2 in the immunopathogenesis of experimental pulmonary tuberculosis. Immunology. 106:2002;257-266.
42. Rhind S.G., Gannon G.A., Shephard R.J., Shek P.N. Indomethacin modulates circulating cytokine responses to strenuous exercise in humans. Cytokine. 19:2002;153-158.
43. Rivoltini L., Carrabba M., Huber V.et al. Immunity to cancer: attack and escape in T lymphocyte-tumor cell interaction. Immunol. Rev. 188:2002;97-113.
44. Robbins B.L., Ranga V.S., Choung K., Bischofberger N., Fridland A. Anti-HIV activity and cellular metabolism of a potential prodrug of the acyclic nucleoside PMPA. Antimicrob. Agents Chemother. 42:1998;612-617.
45. Roth J., Hubschle T., Pehl U., Ross G., Gerstberger R. Influence of systemic treatment with COX inhibitors on LPS induced fever and circulating levels of cytokines and cortisol in guinea pigs. Pflugers Arch. 443:2002;411-417.
46. Saio M., Radoja S., Marino M., Frey A.B. Tumor infiltrating macrophages induce apoptosis in activated CD8+ T cells by a mechanism requiring cell contact and mediated by both the cell associated form of TNF and nitric oxide. J. Immunol. 167:2001;5583-5593.
47. Sanchez S., Martin M.J., Ortiz P.et al. Role of prostaglandins and nitric oxide in gastric damage induced by metamizol in rats. Inflamm. Res. 51:2002;385-392.
48. Senju, S., Hirata, S., Matsuyoshi, H., 2002. Generation and genetic modification of dendritic cells derived from mouse embryonic stem cells. Blood (October 24).
49. Shemi D., Azab A.N., Kaplanski J. Time dependent effect of LPS on PGE2 and TNF production by rat glial brain culture: influence of COX and cytokine inhibitors. J. Endotoxin Res. 6:2000;377-381.
50. Sirota L., Shacham D., Punsky I., Bessler H. Ibuprofen affects pro- and anti-inflammatory cytokine production by mononuclear cells of preterm newborns. Biol. Neonate. 79:2001;103-108.
51. Slomiany B.L., Slomiany A. Aspirin ingestion impairs oral mucosal ulcer healing by inducing membrane bound TNF release. IUBMMB Life. 50:2000;391-395.
52. Slomiany B.L., Piotrowski J., Slomiany A. Up-regulation of gastric mucosal inflammatory responses to H. pylori LPS by aspirin but not indomethacin. J. Endotoxin. Res. 7:2001;203-209.
53. Somasundaram R., Jacob L., Swoboda R.et al. Inhibition of cytolytic T lymphocyte proliferation by autologous CD4+/CD25+ regulatory T cells in a colorectal patient is mediated by transforming growth factor-beta. Cancer Res. 62:2002;5267-5272.
54. Suzuki Y., Yanagawa H., Nishioka Y., Nishimura N., Takeuchi E., Sone S. Efficient generation of dendritic cells from alveolar and pleural macrophages as well as blood monocytes in patients with lung cancer. Lung Cancer. 34:2001;195-205.
55. Trevejo J.M., Marino M.W., Philpott N., Josien R., Elkon K.B., Falk-Pedersen E. TNF-alpha dependent maturation of local dendritic cells is critical for activating the adaptive immune response to virus infection. Proc. Natl. Acad. Sci. 98:2001;12162-12167.
56. Wilkstrom, K., Juhas, M., Jolander, A., 2002. The antiapoptotic effect of LTD 4 involves prevention of caspase-8 activation and bid cleavage. Biochem. J. (December 16).
57. Witkamp R., Monshouwer M. Signal transduction in inflammatory processes, current and future therapeutic targets: a minireview. Vet. Q. 22:2000;11-16.
58. Woo E.Y., Chu C.S., Goletz T.J.et al. Regulatory CD4+/CD25+ T cells in tumors from patients with early stage non-small cell lung cancer and late stage ovarian cancer. Cancer Res. 61:2001;4766-4772.
59. Wu A.J., Hua H., Munson S.H., McDevitt H.O. TNF regulation of CD4+/CD25+ T cell levels in NOD mouse. Proc. Natl. Acad. Sci. U.S.A. 99:2002;12287-12292.
60. Yamada H., Kuroda E., Matsumoto S.et al. PGE2 down-regulates viable BCG induced macrophage cytotoxicity against murine bladder cancer cell MBT-2 in vitro. Clin. Exp. Immunol. 128:2002;52-58.
61. Zidek Z., Frankova D., Holy A. Macrophage activation by antiviral acyclic nucleoside phosphonates in dependence on priming stimuli. Int. J. Immunopharmacol. 22:2000;1121-1129.
62. Zidek, Z., Frankova, D., Holy, A., 2001. Activation by tenofovir of chemokine (RANTES, MIP 1-alpha) and cytokine (TNF-alpha, Il-10, Il-1 beta) production. Antimicrob. Agents Chemother. 45, 3381-3386.